



DATA NOTE

An open dataset of *Plasmodium vivax* genome variation in

1,895 worldwide samples [version 1; peer review: 2 approved]

MalariaGEN, Ishag Adam¹, Mohammad Shafiul Alam², Sisay Alemu³⁻⁵, Chanaki Amaratunga⁶, Roberto Amato⁷, Voahangy Andrianaranjaka⁸, Nicholas M Anstey⁹, Abraham Aseffa³, Elizabeth Ashley^{10,11}, Ashenafi Assefa¹², Sarah Auburn^{9,11,13}, Bridget E Barber^{14,15}, Alyssa Barry¹⁶⁻¹⁸, Dhelio Batista Pereira¹⁹, Jun Cao^{20,21}, Nguyen Hoang Chau²², Kesinee Chotivanich²³, Cindy Chu²⁴, Arjen M. Dondorp¹³, Eleanor Drury⁷, Diego F. Echeverry²⁵, Berhanu Erko²⁶, Fe Espino²⁷, Rick M. Fairhurst²⁸, Abdul Faiz²⁹, María Fernanda Villegas³⁰, Qi Gao²⁰, Lemu Golassa²⁶, Sonia Goncalves⁷, Matthew J Grigg⁹, Yaghoob Hamedi³¹, Tran Tinh Hien²², Ye Htut³², Kimberly J Johnson⁷, Nadira Karunaweera^{33,34}, Wasif Khan², Srivicha Krudsood²³, Dominic P Kwiatkowski⁷, Marcus Lacerda^{35,36}, Benedikt Ley⁹, Pharath Lim^{6,37}, Yaobao Liu^{20,21}, Alejandro Llanos-Cuentas³⁸, Chanthap Lon³⁹, Tatiana Lopera-Mesa⁴⁰, Jutta Marfurt⁹, Pascal Michon⁴¹, Olivo Miotto^{7,13}, Rezika Mohammed⁴², Ivo Mueller¹⁶, Chayadol Namaik-larp⁴³, Paul N Newton^{10,11}, Thuy-Nhien Nguyen^{11,22}, François Nosten^{11,24}, Rintis Noviyanti⁴⁴, Zuleima Pava⁴⁵, Richard D Pearson⁷, Beyene Petros⁴, Aung P Phyoo^{13,46}, Ric N Price^{9,11,13}, Sasithon Pukrittayakamee²³, Awab Ghulam Rahim⁴⁷, Milijaona Randrianarivelojosia^{48,49}, Julian C Rayner⁵⁰, Angela Rumaseb⁹, Sasha V Siegel⁷, Victoria J Simpson⁷, Kamala Thriemer⁹, Alberto Tobon-Castano⁴⁰, Hidayat Trimarsanto⁴⁴, Marcelo Urbano Ferreira^{51,52}, Ivan D Vélez⁵³, Sonam Wangchuk⁵⁴, Thomas E Wellems⁶, Nicholas J White^{11,13}, Timothy William^{55,56}, Maria F Yasnot⁵⁷, Daniel Yilma⁵⁸

¹Faculty of Medicine, University of Khartoum, Khartoum, Sudan

²Infectious Diseases Division, International Centre for Diarrheal Diseases Research, Bangladesh (ICDDR,B), Dhaka, Bangladesh

³MilliporeSigma (Bioreliance), Rockville, USA

⁴Armauer Hansen Research Unit (AHRI), Addis Ababa, Ethiopia

⁵Addis Ababa University, Addis Ababa, Ethiopia

⁶National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, USA

⁷Wellcome Sanger Institute, Hinxton, UK

⁸Université d'Antananarivo, Antananarivo, Madagascar

⁹Global and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, Australia

¹⁰Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit, Microbiology Laboratory, Mahosot Hospital, Vientiane, Lao People's Democratic Republic

¹¹Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK

- ¹²Ethiopian Public Health Institute, Addis Ababa, Ethiopia
- ¹³Mahidol-Oxford Tropical Medicine Research Unit, Mahidol University, Bangkok, Thailand
- ¹⁴Menzies School of Health Research, Darwin, Australia
- ¹⁵QIMR Berghofer Medical Research Institute, Brisbane, Australia
- ¹⁶Walter and Eliza Hall Institute, Parkville, Australia
- ¹⁷Deakin University, Geelong, Australia
- ¹⁸Burnet Institute, Melbourne, Australia
- ¹⁹Centro de Pesquisa em Medicina Tropical de Rondônia, Porto Velho, Brazil
- ²⁰National Health Commission Key Laboratory of Parasitic Disease Control and Prevention, Jiangsu Provincial Key Laboratory on Parasite and Vector Control Technology, Jiangsu Institute of Parasitic Diseases, Wuxi, China
- ²¹Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China
- ²²Oxford University Clinical Research Unit, Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam
- ²³Mahidol University, Bangkok, Thailand
- ²⁴Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot, Thailand
- ²⁵Departamento de Microbiología, Facultad de Salud, Universidad del Valle, Cali, Colombia
- ²⁶Aklilu Lemma Institute of Pathobiology, Addis Ababa University, Addis Ababa, Ethiopia
- ²⁷Research Institute for Tropical Medicine, Department of Health, Manila, Philippines
- ²⁸National Institutes of Health (NIH), Bethesda, USA
- ²⁹Dev Care Foundation, Dhaka, Bangladesh
- ³⁰Centro de Investigaciones Clínicas, Cali, Colombia
- ³¹Infectious and Tropical Diseases Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
- ³²Department of Medical Research, Yangon, Myanmar
- ³³University of Colombo, Colombo, Sri Lanka
- ³⁴School of Public Health, Harvard University, Boston, USA
- ³⁵Instituto de Pesquisa Clínica Carlos Borborema, Fundação de Medicina Tropical Dr Heitor Vieira Dourado, Manaus, Brazil
- ³⁶Instituto Leônidas & Maria Deane, Fundação Oswaldo Cruz, Manaus, Brazil
- ³⁷Parsons Corporation, Walter Reed Army Institute of Research (WRAIR), Silver Spring, USA
- ³⁸Cayetano Heredia University, Lima, Peru
- ³⁹National Institute of Allergy and Infectious Diseases, Phnom Penh, Cambodia
- ⁴⁰Universidad de Antioquia, Medellín, Colombia
- ⁴¹National University of Vanuatu, Port-Vila, Vanuatu
- ⁴²Department of Internal Medicine, University of Gondar, Gondar, Ethiopia
- ⁴³Umphang Hospital, Tak, Thailand
- ⁴⁴Eijkman Institute for Molecular Biology, Jakarta, Indonesia
- ⁴⁵Centro Internacional de Entrenamiento e Investigaciones Médicas, Cali, Colombia
- ⁴⁶Shoklo Malaria Research Unit, Bangkok, Thailand
- ⁴⁷Nangarhar Medical Faculty, Nangarhar University, Ministry of Higher Education, Jalalabad, Afghanistan
- ⁴⁸Institut Pasteur de Madagascar, Antananarivo, Madagascar
- ⁴⁹Universités d'Antananarivo et de Mahajanga, Antananarivo, Madagascar
- ⁵⁰Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK
- ⁵¹Universidade de São Paulo, São Paulo, Brazil
- ⁵²Institute of Hygiene and Tropical Medicine, NOVA University of Lisbon, Lisbon, Portugal
- ⁵³Universidad de Antioquia, Medellín, Colombia
- ⁵⁴Royal Center for Disease Control, Department of Public Health, Ministry of Health, Thimphu, Bhutan
- ⁵⁵Clinical Research Centre, Queen Elizabeth Hospital, Sabah, Malaysia
- ⁵⁶Infectious Diseases Society Sabah-Menzies School of Health Research Clinical Research Unit, Kota Kinabalu, Sabah, Malaysia
- ⁵⁷Grupo de Investigaciones Microbiológicas y Biomédicas de Córdoba-GIMBIC, Universidad de Córdoba, Montería, Colombia
- ⁵⁸Jimma University, Jimma, Ethiopia

V1 First published: 14 Apr 2022, 7:136
<https://doi.org/10.12688/wellcomeopenres.17795.1>

Latest published: 14 Apr 2022, 7:136
<https://doi.org/10.12688/wellcomeopenres.17795.1>

Open Peer Review



Approval Status 

Abstract

This report describes the MalariaGEN Pv4 dataset, a new release of curated genome variation data on 1,895 samples of *Plasmodium vivax* collected at 88 worldwide locations between 2001 and 2017. It includes 1,370 new samples contributed by MalariaGEN and VivaxGEN partner studies in addition to previously published samples from these and other sources. We provide genotype calls at over 4.5 million variable positions including over 3 million single nucleotide polymorphisms (SNPs), as well as short indels and tandem duplications. This enlarged dataset highlights major compartments of parasite population structure, with clear differentiation between Africa, Latin America, Oceania, Western Asia and different parts of Southeast Asia. Each sample has been classified for drug resistance to sulfadoxine, pyrimethamine and mefloquine based on known markers at the *dhfr*, *dhps* and *mdr1* loci. The prevalence of all of these resistance markers was much higher in Southeast Asia and Oceania than elsewhere. This open resource of analysis-ready genome variation data from the MalariaGEN and VivaxGEN networks is driven by our collective goal to advance research into the complex biology of *P. vivax* and to accelerate genomic surveillance for malaria control and elimination.

Keywords

malaria, plasmodium vivax, genomics, data resource, genomic epidemiology

	1	2
version 1		
14 Apr 2022	view	view
1. Daniel Neafsey , Harvard T.H. Chan School of Public Health, Boston, USA Broad Institute of MIT and Harvard, Cambridge, Cambridge, USA		
2. Jonathan J. Juliano , University of North Carolina School of Medicine, Chapel Hill, USA		
Any reports and responses or comments on the article can be found at the end of the article.		

Corresponding author: MalariaGEN (support@malaria-gen.net)

Author roles: **Adam I:** Investigation, Resources, Writing – Review & Editing; **Alam MS:** Investigation, Resources, Writing – Review & Editing; **Alemu S:** Investigation, Resources, Writing – Review & Editing; **Amaratunga C:** Investigation, Resources, Writing – Review & Editing; **Amato R:** Conceptualization, Data Curation, Formal Analysis, Investigation, Project Administration, Software, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing; **Andrianaranjaka V:** Investigation, Resources, Writing – Review & Editing; **Anstey NM:** Investigation, Resources, Writing – Review & Editing; **Aseffa A:** Investigation, Resources, Writing – Review & Editing; **Ashley E:** Investigation, Resources, Writing – Review & Editing; **Assefa A:** Investigation, Resources, Writing – Review & Editing; **Auburn S:** Investigation, Resources, Writing – Review & Editing; **Barber BE:** Investigation, Resources, Writing – Review & Editing; **Barry A:** Investigation, Resources, Writing – Review & Editing; **Batista Pereira D:** Investigation, Resources, Writing – Review & Editing; **Cao J:** Investigation, Resources, Writing – Review & Editing; **Chau NH:** Investigation, Resources, Writing – Review & Editing; **Chotivanich K:** Investigation, Resources, Writing – Review & Editing; **Chu C:** Investigation, Resources, Writing – Review & Editing; **Dondorp AM:** Investigation, Resources, Writing – Review & Editing; **Drury E:** Investigation, Writing – Review & Editing; **Echeverry DF:** Investigation, Resources, Writing – Review & Editing; **Erko B:** Investigation, Resources, Writing – Review & Editing; **Espino F:** Investigation, Resources, Writing – Review & Editing; **Fairhurst RM:** Investigation, Resources, Writing – Review & Editing; **Faiz A:** Investigation, Resources, Writing – Review & Editing; **Fernanda Villegas M:** Investigation, Resources, Writing – Review & Editing; **Gao Q:** Investigation, Resources, Writing – Review & Editing; **Golassa L:** Investigation, Resources, Writing – Review & Editing; **Goncalves S:** Investigation, Project Administration, Writing – Review & Editing; **Grigg MJ:** Investigation, Resources, Writing – Review & Editing; **Hamedi Y:** Investigation, Resources, Writing – Review & Editing; **Hien TT:** Investigation, Resources, Writing – Review & Editing; **Htut Y:** Investigation, Resources, Writing – Review & Editing; **Johnson KJ:** Investigation, Project Administration, Writing – Review & Editing; **Karunaweera N:** Investigation, Resources, Writing – Review & Editing; **Khan W:** Investigation, Resources, Writing – Review & Editing; **Krudsood S:** Investigation, Resources, Writing – Review & Editing; **Kwiatkowski DP:** Conceptualization, Formal Analysis, Funding Acquisition, Investigation, Project Administration, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing; **Lacerda M:** Investigation, Resources, Writing – Review & Editing; **Ley B:** Investigation, Resources, Writing – Review & Editing; **Lim P:** Investigation, Resources, Writing – Review & Editing; **Liu Y:** Investigation, Resources, Writing – Review & Editing; **Llanos-Cuentas A:** Investigation, Resources, Writing – Review & Editing; **Lon C:** Investigation, Resources, Writing – Review & Editing; **Lopera-Mesa T:** Investigation, Resources, Writing – Review & Editing; **Marfurt J:** Investigation, Resources, Writing – Review & Editing; **Michon P:** Investigation, Resources, Writing – Review & Editing; **Miotto O:** Data Curation, Formal Analysis, Investigation, Project Administration, Software, Writing – Review & Editing; **Mohammed R:** Investigation, Resources, Writing – Review & Editing; **Mueller I:** Investigation, Resources, Writing – Review & Editing; **Namaik-larp C:** Investigation, Resources, Writing – Review & Editing; **Newton PN:** Investigation, Resources, Writing – Review & Editing; **Nguyen TN:** Investigation, Resources, Writing – Review & Editing; **Nosten F:** Investigation, Resources, Writing – Review & Editing; **Noviyanti R:** Investigation, Resources, Writing – Review & Editing; **Pava Z:** Investigation, Resources, Writing – Review & Editing; **Pearson RD:** Conceptualization, Data Curation, Formal Analysis, Investigation, Project Administration, Software, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing; **Petros B:** Investigation, Resources, Writing – Review & Editing; **Phyo AP:** Investigation, Resources, Writing – Review & Editing; **Price RN:** Investigation, Resources, Writing – Review & Editing; **Pukrittayakamee S:** Investigation, Resources, Writing – Review & Editing; **Rahim AG:** Investigation, Resources, Writing – Review & Editing; **Randrianarivelosia M:** Investigation, Resources, Writing – Review & Editing; **Rayner JC:** Investigation, Resources, Writing – Review & Editing; **Rumaseb A:** Investigation, Resources, Writing – Review & Editing; **Siegel SV:** Data Curation, Formal Analysis, Investigation, Project Administration, Writing – Original Draft Preparation, Writing – Review & Editing; **Simpson VJ:** Investigation, Project Administration, Writing – Review & Editing; **Thriemer K:** Investigation, Resources, Writing – Review & Editing; **Tobon-Castano A:** Investigation, Resources, Writing – Review & Editing; **Trimarsanto H:** Investigation, Resources, Writing – Review & Editing; **Urbano Ferreira M:** Investigation, Resources, Writing – Review & Editing; **Vélez ID:** Investigation, Resources, Writing – Review & Editing; **Wangchuk S:** Investigation, Resources, Writing – Review & Editing; **Wellems TE:** Investigation, Resources, Writing – Review & Editing; **White NJ:** Investigation, Resources, Writing – Review & Editing; **William T:** Investigation, Resources, Writing – Review & Editing; **Yasnot MF:** Investigation, Resources, Writing – Review & Editing; **Yilma D:** Investigation, Resources, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: This research was funded by the Wellcome Trust (206194, 108413/A/15/D, 204911); the Medical Research Council UK and the Department for International Development (DFID) (MR/M006212/1); and the Bill & Melinda Gates Foundation (OPP1204628, INV-001927).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2022 MalariaGEN *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: MalariaGEN, Adam I, Alam MS *et al.* **An open dataset of *Plasmodium vivax* genome variation in 1,895 worldwide samples [version 1; peer review: 2 approved]** Wellcome Open Research 2022, 7:136 <https://doi.org/10.12688/wellcomeopenres.17795.1>

First published: 14 Apr 2022, 7:136 <https://doi.org/10.12688/wellcomeopenres.17795.1>

Background

Plasmodium vivax is the second most common cause of human malaria, with an extensive geographical range^{1,2}. *P. vivax* has a number of biological features that distinguish it from the more widely studied *P. falciparum*. Importantly, *P. vivax* establishes dormant forms in the liver that are refractory to most antimalarial drugs, resulting in relapsing infections that represent a major challenge to malaria elimination³⁻⁵. Additionally, a cryptic endosplenic life-cycle results in a large hidden splenic reservoir of *P. vivax* parasites^{6,7} which sustains a high prevalence of low-density asymptomatic blood stage infections. *P. vivax* is uncommon in much of sub-Saharan Africa, and this is thought to be primarily due to the high frequency of the Duffy negative blood group that inhibits invasion by this species, although the parasite can sometimes break through this protection by unknown mechanisms⁸. Clinical disease occurs at lower circulating parasite densities for *P. vivax* than for *P. falciparum*, making the detection and characterisation of infections considerably more difficult³. Analysis of *P. vivax* genome variation is technically challenging for a number of reasons, particularly the difficulty of getting high quality sequence data due to low parasite density in clinical blood samples. An additional challenge is high levels of within-host diversity in some peripheral blood samples, that can be due to either superinfection or cotransmission⁹ and is exacerbated by relapsing infections or spillover from extravascular reservoirs. It is widely accepted that *P. vivax* is likely to be more challenging to eliminate than *P. falciparum*, and indeed, in countries approaching elimination the proportion of malaria due to *vivax* has increased^{1,2}.

Here we report a new data release from the MalariaGEN *Plasmodium vivax* Genome Variation Project which was established in 2010 to enable malaria researchers to integrate parasite genome sequencing into clinical and epidemiological studies of *P. vivax* (<https://www.malariagen.net/parasite/p-vivax-genome-variation>). Genome sequencing was performed at the Wellcome Sanger Institute and a standardised analysis pipeline was used for variant discovery and genotyping. Sequence data and genotype calls were returned to partners for use in their own analyses and publications in line with MalariaGEN's guiding principles on equitable data sharing¹⁰. Each data release to partners is given a version number and the current version is called Pv4.

The Pv4 dataset comprises 1,895 samples from 27 countries, most of which were sequenced at the Wellcome Sanger Institute. Of the 1,306 samples that have not previously been published, the majority came from a collaboration between MalariaGEN and the VivaxGEN network (<http://menzies.edu.au/vivaxGEN>) led by Menzies School of Health Research, and from a multicentre clinical trial led by GlaxoSmithKline^{11,12}. We have also included 292 samples from a previous MalariaGEN publication¹³ and 297 samples from previously published studies by other research groups¹⁴⁻¹⁶. All samples have been reanalysed using a standardised pipeline to minimise potential artefacts arising from different sequencing protocols.

To make these data as useful as possible to other researchers, we provide curated genotype calls on millions of SNPs, indels,

and tandem duplications. We have classified samples for evidence of resistance to sulfadoxine, pyrimethamine and mefloquine based on known genetic markers. Each sample is evaluated for within-host diversity and for its location in the global parasite population structure. This new data release increases the sample size of *P. vivax* genome variation data by more than threefold, and it provides an open resource of curated, analysis-ready data with many potential applications both for basic scientific research and in building genomic surveillance tools for malaria control and elimination.

Resource data

The 1,895 samples in the Pv4 dataset were collected from 88 locations in 27 countries in Asia, Oceania, Latin America and Africa, mostly between 2001 and 2017 (Table 1–Table 4). 1,026 samples were collected by the VivaxGEN network, a global collaboration using translational genomics to develop new molecular surveillance tools to support the elimination of *P. vivax*. A further 357 samples were collected as part of drug safety and efficacy trials led by GlaxoSmithKline in Latin America, Asia and Africa^{11,12}. There were 215 samples from other MalariaGEN partner studies, the details of which can be found in Table 3. Finally, we have integrated 297 previously-published samples that were sequenced by the Broad Institute, the University of North Carolina at Chapel Hill and the Wellcome Sanger Institute as part of other research collaborations¹⁴⁻¹⁶. Since the dataset included samples from multiple sequencing labs with different protocols it was necessary to perform systematic curation to minimise the introduction of biases.

All 1,598 samples contributed by MalariaGEN partners were sequenced at the Wellcome Sanger Institute using the Illumina platform. For the 297 samples published by other research groups, raw reads were obtained from the European Nucleotide Archive (PRJNA240356-PRJNA240533 and PRJNA295233). We mapped the sequence reads against the *P. vivax* P01 v1 reference genome and the median depth of coverage was 26x averaged across the whole genome and across all samples.

We constructed an analysis pipeline for variant discovery and genotyping, including stringent quality control filters as outlined in the Methods section. We discovered genome variation spanning 16% of the *P. vivax* genome (~4.5 million positions), with variation falling predominantly within non-coding regions (Table 5). The majority of variation was in the form of SNPs (3,083,454), with the remaining 1,487,602 variants consisting of short indels, and occasionally more complex combinations of SNPs and indels that were at least three alleles. For the purpose of analysis, we excluded all variants in subtelomeric and internal hypervariable regions, mitochondrial and apicoplast genomes. A total of 945,649 SNPs (of which 911,901 were biallelic) and 358,335 indels (or SNP/indel combinations) passed this filtration step. The pass rates for SNPs and indels in coding regions (53%, 50%) were considerably higher than SNPs and indels in non-coding regions (22%, 18%). Short variant calls in both VCF and zarr format can be found via the data resource page (<https://www.malariagen.net/resource/30>).

As part of a detailed curation process, we removed samples with (i) unverified or incomplete sample collection information; (ii) evidence of co-infection with other *Plasmodium* species; (iii) more than one technical replicate or time course sampling (in which case we retained the sample for which the proportion of the genome covered was the greatest); (iv) low coverage, or (v) evidence of being an extreme genetic outlier. We directly compared data from MalariaGEN partner studies with those from other research groups in three locations where samples were available from both sources: Iquitos, Peru; Oddar Meanchey; Cambodia; Oromia, Ethiopia. We found no stratification by data source and no indications of significant biases. In total, we obtained 1,072 high-quality samples from 27 countries (Table 1).

The genetic structure of the global parasite population largely reflects its geographic regional structure¹³ as recapitulated by a principal component analysis of all samples based on their SNP genotypes (Figure 1a). Here we divided samples into seven regional sub-populations of parasites with a high degree of geographic and genetic proximity (41/1,072 high-quality samples were not assigned to a regional sub-population giving a final analysis set of 1,031 samples). However, geography is not the only factor influencing the population structure, as different regions are impacted by a range of epidemiological and environmental effects, such as differences in transmission intensity, vector species and history of antimalarial drug usage. An example of this can be seen in the varying levels of regional population structure as illustrated with a neighbour-joining

Table 1. Count of samples in the dataset. Countries are grouped into seven geographic regions based on their geographic and genetic characteristics. For each country, the table reports: the number of distinct sampling locations; the total number of samples sequenced; the number of high-quality samples; the number of high-quality samples included in the analysis; and the percentage of samples collected between 2015–2017, the most recent sampling period in the dataset. 70 samples are from countries that are genetically distinct from those from the seven regions, and a further 48 samples from Bangkok could not be assigned to either the WSEA or ESEA region. These 118 samples (of which 41 passed QC) are classified as unassigned. The breakdown by site is reported in Table 2 and the list of contributing studies in Table 3 and Table 4.

Region	Country	Sampling locations	Sequenced samples	QC pass samples	Analysis set samples	% analysis samples 2015–2017
Latin America (LAM)	Brazil	6	71	21	21	24%
	Colombia	12	112	67	67	39%
	El Salvador	1	2	1	1	0%
	Mexico	5	20	20	20	0%
	Nicaragua	1	1	1	1	0%
	Panama	1	1	1	1	0%
	Peru	6	123	48	48	15%
Africa (AF)	Ethiopia	7	203	137	137	39%
Western Asia (WAS)	Afghanistan	2	250	36	36	81%
	India	4	14	5	5	0%
	Iran	1	15	5	5	0%
	Sri Lanka	1	2	1	1	0%
Western Southeast Asia (WSEA)	Western Thailand	5	141	127	127	7%
Eastern Southeast Asia (ESEA)	Cambodia	7	236	172	172	28%
	Northeastern Thailand	2	3	2	2	0%
	Vietnam	6	139	103	103	88%
Maritime Southeast Asia (MSEA)	Malaysia	2	109	73	73	0%
	Philippines	1	6	3	3	100%
Oceania (OCE)	Indonesia	2	282	191	191	18%
	Papua New Guinea	4	47	17	17	0%

Region	Country	Sampling locations	Sequenced samples	QC pass samples	Analysis set samples	% analysis samples 2015-2017
Unassigned samples (unassigned)	Bangladesh	1	28	6	0	
	Bhutan	1	9	2	0	
	China	1	5	5	0	
	Madagascar	3	4	4	0	
	Mauritania	1	1	1	0	
	Myanmar	2	9	8	0	
	North Korea	1	1	1	0	
	Sudan	1	13	4	0	
	Thailand (Bangkok)	1	48	10	0	
Total		88	1,895	1,072	1,031	30%

tree (Figure 1b), with maritime Southeast Asia having large numbers of highly related parasites being the most striking example, as previously described¹⁷. These regional classifications are intentionally broad, and therefore overlook many interesting aspects of local population structure. Sample information including partner study information, location and year of collection, ENA accession numbers, QC information and region assignment can be found on the resource page (<https://www.malariagen.net/resource/30>).

Analysis of F_{ws} , a measure of within-host diversity, shows that in all regions, the majority of samples have $F_{ws} > 0.95$, which to a first approximation indicates that the infection is dominated by a clonal population of parasites. The proportions of such clonal samples were highest in Latin America (135/159, 85%), Maritime SE Asia (59/76, 78%) and Africa (102/137, 74%). In contrast, over 40% of samples from Eastern SE Asia (116/277, 42%) and Oceania (88/208, 42%) have $F_{ws} < 0.95$, indicating the presence of more complex infections. Interestingly, these results are in contrast to those in *P. falciparum* where complex infections are more common in Africa than in SE Asia¹⁸, reflecting the different epidemiology of the two diseases. A file of F_{ws} values for all QC pass samples can be found in the data resource (<https://www.malariagen.net/resource/30>).

We genotyped tandem duplications using a novel two-stage process, where we first discovered base pair resolution breakpoints using a combination of read depth and split reads, and then genotyped samples at these discovered breakpoints using a combination of read depth and read pairs mapped in a tail-to-tail configuration. This hybrid approach allows us to assess the presence of known tandem duplications also in samples with low and uneven coverage or in complex infections. Compared to our previous release, the improved method now has the ability to distinguish unique breakpoints, as well as the distinct chromosomal fragment formations of these tandem duplication events.

We discovered seven pairs of distinct tandem duplication breakpoints in four different regions of the genome (Table 6). Most breakpoints (5/7) were found to be homopolymer A/T repeats of ≥ 11 nucleotides in non-coding regions. The most common duplications were found around *dbp*, with two different sets of breakpoints previously described as the “Malagasy” and “Cambodian” duplications^{19,20}. Interestingly, we found that the “Cambodian” duplication was common and widespread, with the highest proportion of samples in Africa, moderate frequencies in western/eastern Southeast Asia, and lower frequencies in maritime Southeast Asia/Oceania. In sharp contrast, the “Malagasy” duplication was only seen in African isolates.

We previously reported on a chromosome 14 duplication encompassing the gene PVP01_1468200 (conserved protein with unknown function previously annotated as PVX_101445)¹³, and can now show that there are three different sets of breakpoints. The most common duplication is the short 3.5kb duplication which includes only the single gene PVP01_1468200. All three duplications are seen exclusively in Oceania. The tandem duplication calls for all samples can be found in the data resource (<https://www.malariagen.net/resource/30>).

Molecular mechanisms of resistance in *P. vivax* are poorly understood²¹, which restricts the ability to perform drug resistance sample classification to a very limited set of published and well-recognised genetic markers. We correspondingly classified all samples using a set of basic heuristics into four types of inferred drug resistance, with Table 7 summarising the frequency of samples classified as resistant in different geographical regions. Overall, we observed higher prevalence of inferred resistance in Southeast Asia and Oceania than elsewhere, with 18% samples in Western Southeast Asia inferred resistant to all three drugs considered (sulfadoxine, pyrimethamine and mefloquine). Notably, this is intended simply to provide analysis context, and cannot be considered as an accurate reflection of the current epidemiological situation.

Table 2. Breakdown of analysis set samples by geography. Sites are divided into seven regions as described in the main text. Note that samples from Pakchong and Sisaket in eastern Thailand have been assigned to the Eastern SE Asia (ESEA) region whereas samples from other regions in Thailand have been assigned to the Western SE Asia (WSEA) region. 41 samples that passed QC but were not assigned to one of the seven regions have been excluded from analyses.

Region	Country	First-level administrative division	Site	Sequenced samples	Analysis set samples
LAM	Brazil	Brazil	Brazil	6	4
		Brazil: Acre	Acrelândia	7	1
			Plácido de Castro	13	1
		Brazil: Amazonas	Manaus	37	14
		Brazil: Para	Belem	1	1
		Brazil: Rondonia	Porto Velho	7	0
	Colombia	Colombia	Colombia	3	2
		Colombia: Antioquia	Antioquia	8	2
		Colombia: Bolivar	Bolivar	1	0
		Colombia: Choco	Choco	26	13
			Pichimá	1	0
		Colombia: Cordoba	Cordoba	3	3
			Córdoba	1	1
			Tierralta	43	37
		Colombia: Narino	Tumaco	2	2
		Colombia: Risaralda	Santa Cecilia	16	3
			Colombia: Valle del Cauca	Buenaventura	3
		Cali		5	1
	El Salvador	El Salvador	El Salvador	2	1
	Mexico	Mexico: Chiapas	Carrillo	1	1
			Frontera Hidalgo	1	1
			Huehuetán	1	1
			Tapachula	16	16
			Tuxtla Chico	1	1
	Nicaragua	Nicaragua	Nicaragua	1	1
	Panama	Panama	Panama	1	1
	Peru	Peru: Loreto	Iquitos	89	16
			Mazán	10	10
			Puerto America	4	4
Santo Tomás			10	9	
Peru: Madre de Dios		Delta 1	6	5	
Peru: Piura		Sullana	4	4	

Region	Country	First-level administrative division	Site	Sequenced samples	Analysis set samples
AF	Ethiopia	Ethiopia: Amhara	Amhara	19	17
			Gondar	28	11
		Ethiopia: Oromia	Batu	3	2
			Bishoftu	4	0
			Jimma	44	26
			Oromia	69	51
		Ethiopia: SNNaP	South Nations Nationalities and Peoples' Region	36	30
WAS	Afghanistan	Afghanistan: Laghman	Laghman	95	10
		Afghanistan: Nangarhar	Jalalabad	155	26
	India	India	India	2	2
			India (returning traveller)	1	0
		India: Madhyapradesh	Indore (returning traveller)	1	0
		India: Maharashtra	Mumbai (returning traveller)	2	1
		India: Tamil Nadu	Chennai	8	2
	Iran	Iran	15	5	
Sri Lanka	Sri Lanka: Monaragala	Kataragama	2	1	
WSEA	Thailand	Thailand: Kanchanaburi	Kanchanaburi	20	20
		Thailand: Tak	Mae Sot	4	4
			Tak	42	40
			Umphang	11	5
			Wangpha	64	58
ESEA	Cambodia	Cambodia: Battambang	Battambang	9	9
		Cambodia: Kampot	Kampot	9	9
		Cambodia: Koh Kong	Takavit	2	1
		Cambodia: Oddar Meanchey	Oddar Meanchey	133	104
		Cambodia: Pailin	Pailin	1	1
		Cambodia: Pursat	Pursat	79	46
		Cambodia: Ratanakiri	Ratanakiri	3	2
	Thailand	Thailand: Nakhon Ratchasima	Pakchong	1	1
		Thailand: Sisaket	Sisaket	2	1
	Vietnam	Vietnam	Vietnam	1	0
			Vietnam: Binh Phuoc	Binh Phuoc	30
			Dak O	31	26
		Vietnam: Gia Lai	Krong Pa	34	28
		Vietnam: Ho Chi Minh	Ho Chi Min	42	33
		Viet Anh Ward	1	1	

Region	Country	First-level administrative division	Site	Sequenced samples	Analysis set samples
MSEA	Malaysia	Malaysia: Sabah	Sabah	108	73
		Malaysia: Selangor	Klang	1	0
	Philippines	Philippines: Palawan	Rio Tuba	6	3
OCE	Indonesia	Indonesia: Papua	Papua Indonesia	253	175
			Papua Indonesia (returning traveller)	29	16
	Papua New Guinea	Papua New Guinea	Papua New Guinea	8	1
			Papua New Guinea (returning traveller)	3	0
			Papua New Guinea: East Sepik	6	0
			Papua New Guinea: Madang	30	16
Total				1,777	1,031

Table 3. MalariaGEN studies contributing samples.

Study ID	Study title	Contact	Samples	Sites
1044-PF-KH-FAIRHURST	Genomics of parasite clearance and recrudescence rates in Cambodia	Thomas E Wellems twellems@niaid.nih.gov	82	Pursat (Cambodia), Ratanakiri (Cambodia)
1046-PV-BR-FERRERIA	Developing the <i>Plasmodium Vivax</i> Genome Variation Project with partners in Brazil	Marcelo Ferreira muferre@usp.br	5	Brazil (Brazil)
1047-PV-LK-KARUNAWEERA	Developing the <i>Plasmodium Vivax</i> Genome Variation Project with partners in Sri Lanka	Nadira Karunaweera nadira@parasit.cmb.ac.lk	2	Kataragama (Sri Lanka)
1049-PV-VN-BONI	Developing the <i>Plasmodium Vivax</i> Genome Variation Project with partners in Vietnam	Tran Tinh Hien hientt@oucru.org	13	Binh Phuoc (Vietnam), Viet Anh Ward (Vietnam)
1050-PV-PN-MUELLER	Developing the <i>Plasmodium Vivax</i> Genome Variation Project with partners in Papua New Guinea	Ivo Mueller ivomueller@fastmail.fm	20	East Sepik (Papua New Guinea), Madang (Papua New Guinea)
1052-PF-TRAC-WHITE	Tracking Resistance to Artemisinin Collaboration (TRAC)	Elizabeth Ashley liz@tropmedres.ac	4	Bago (Myanmar), Binh Phuoc (Vietnam), Sisaket (Thailand)
1098-PF-ET-GOLASSA	The prevalence of asymptomatic carriage; emergence of parasite mutations conferring anti-malaria drug resistance; and G6PD deficiency in the human population, as possible impediments to malaria elimination in Ethiopia	Lemu Golassa lgolassa@gmail.com	88	Amhara (Ethiopia), Oromia (Ethiopia)
1102-PF-MG-RANDRIANARIVELOJOSIA	Genotyping <i>P. falciparum</i> and <i>P. vivax</i> in Madagascar	Milijaona Randrianarivejosia milijaon@pasteur.mg	1	Maevatanana (Madagascar)

Study ID	Study title	Contact	Samples	Sites
1128-PV-MULTI-GSK	A global survey of <i>P. vivax</i> genome variation in samples from two GSK phase 3 clinical trials of tafenoquine in Pv relapse/reinfection (trial names DETECTIVE and GATHER)	Anup Pingle anup.s.pingle@gsk.com	357	Bangkok (Thailand), Cali (Colombia), Gondar (Ethiopia), Ho Chi Min (Vietnam), Iquitos (Peru), Jimma (Ethiopia), Mae Sot (Thailand), Manaus (Brazil), Oddar Meanchey (Cambodia), Porto Velho (Brazil), Rio Tuba (Philippines), Umphang (Thailand)
1154-PV-TH-PRICE	Characterisation of drug resistance in <i>P. falciparum</i> and <i>P. vivax</i> populations from Indonesia and Thailand	Sarah Auburn Sarah.Auburn@menzies.edu.au	359	Papua Indonesia (Indonesia), Tak (Thailand), Wangpha (Thailand)
1157-PV-MULTI-PRICE	<i>P. vivax</i> SNP barcode for mapping parasite transmission and spread within and across borders: a vivaxGEN initiative	Sarah Auburn Sarah.Auburn@menzies.edu.au	667	Anhui (China), Antioquia (Colombia), Bangladesh (Bangladesh), Batu (Ethiopia), Bhutan (Bhutan), Binh Phuoc (Vietnam), Bishoftu (Ethiopia), Bolivar (Colombia), Choco (Colombia), Colombia (Colombia), Cordoba (Colombia), Córdoba (Colombia), Dak O (Vietnam), El Salvador (El Salvador), India (returning traveller) (India), Indore (returning traveller) (India), Iran (Iran), Jalalabad (Afghanistan), Kassala (Sudan), Klang (Malaysia), Krong Pa (Vietnam), Laghman (Afghanistan), Papua Indonesia (returning traveller) (Indonesia), Papua New Guinea (returning traveller) (Papua New Guinea), Pichimá (Colombia), Sabah (Malaysia), Santa Cecilia (Colombia), South Nations Nationalities and Peoples' Region (Ethiopia), Tierralta (Colombia)
Total			1,598	

The only combination therapy described here is sulfadoxine/pyrimethamine (SP), with SP resistant samples being classified into three overlapping types: (i) carrying the *dhfr* 117T allele, associated with pyrimethamine resistance; (ii) the *dhps* 383G allele, associated with sulfadoxine resistance; (iii) carrying the *dhfr* quadruple mutant, which is associated with SP failure. Amino acid calls at drug resistance loci, inferred drug resistance phenotypes and a document detailing heuristics used to infer these phenotypes can be found in the data resource (<https://www.malariagen.net/resource/30>).

Methods

DNA sequencing

Standard laboratory protocols were used to determine DNA quantity and proportion of human DNA in each sample as previously described¹³. 1,622 samples passing thresholds were put forward for whole genome Illumina paired-end sequencing.

The majority of these were from MalariaGEN studies but 24 were sequenced at the Wellcome Sanger Institute in a collaboration between Julian Rayner and Eugenia Lo¹⁵. A further 273 samples were downloaded from the SRA^{14,16}. All 1,895 samples were analysed.

Read mapping and coverage analysis

Reads mapping to the human reference genome were discarded before all analyses, and the remaining reads were mapped to the *P. vivax* P01 v1 reference genome²² (ftp://ftp.sanger.ac.uk/pub/project/pathogens/gff3/2016-10/PvivaxP01_genome.fasta.gz) using *bwa mem*²³ version 0.7.15 with *-M* parameter to mark shorter split hits as secondary.

Two of the steps in the pipeline (base quality score recalibration and variant quality score recalibration) require a set of known variants. For both of these steps we used the PASS

Table 4. External studies contributing samples.

External Study ID	Manuscript title	Citation	Samples	Sites
X0001-PV-MULTI-HUPALO2016	Population genomics studies identify signatures of global dispersal and drug resistance in <i>Plasmodium vivax</i>	pubmed 27348298	195	Acrelândia (Brazil), Ampasimpotsy (Madagascar), Belem (Brazil), Brazil (Brazil), Buenaventura (Colombia), Carrillo (Mexico), Chennai (India), Choco (Colombia), Delta 1 (Peru), El Salvador (El Salvador), Frontera Hidalgo (Mexico), Huehuetán (Mexico), India (India), Iquitos (Peru), Kanchanaburi (Thailand), Laiza township (Myanmar), Madagascar (Madagascar), Madang (Papua New Guinea), Mauritania I (Mauritania), Mazán (Peru), Nicaragua (Nicaragua), North Korea (North Korea), Pailin (Cambodia), Pakchong (Thailand), Panama (Panama), Papua New Guinea (Papua New Guinea), Plácido de Castro (Brazil), Puerto America (Peru), Santo Tomás (Peru), Sullana (Peru), Takavit (Cambodia), Tapachula (Mexico), Tierralta (Colombia), Tumaco (Colombia), Tuxtla Chico (Mexico), Vietnam (Vietnam)
X0002-PV-KH-PAROBK2016	Selective sweep suggests transcriptional regulation may underlie <i>Plasmodium vivax</i> resilience to malaria control measures in Cambodia	pubmed 27911780	78	Battambang (Cambodia), Kampot (Cambodia), Oddar Meanchey (Cambodia)
X0009-PV-ET-LO	Frequent expansion of <i>Plasmodium vivax</i> Duffy Binding Protein in Ethiopia and its epidemiological significance	pubmed 31509523	24	Jimma (Ethiopia)
Total			297	

Table 5. Summary of discovered variant positions. We divide variant positions into those containing single nucleotide polymorphisms (SNPs) and non-SNPs (indels and combinations of SNPs and indels at the same position). We then further sub-divide each of these into those within exons (coding) and those in intronic or intergenic regions (non-coding). We further sub-divide SNPs into those containing only two alleles (bi-allelic) or those containing three or more alleles (multi-allelic). Discovered variant positions are unique positions in the reference genome where either SNP or indel variation was discovered by our analysis pipeline. Pass variant positions are the subset of discovered positions that passed our quality filters. Alleles per pass position shows the mean number of distinct alleles at each pass position; biallelic variants have two alleles by definition.

Type	Coding	Multi-allelic	Discovered variant positions	Pass variant positions	% pass	Alleles per pass position
SNP	Coding	Bi-allelic	827,373	440,222	53%	2.0
		Multi-allelic	40,311	17,111	42%	3.0
	Non-coding	Bi-allelic	1,927,558	471,679	24%	2.0
		Multi-allelic	288,212	16,637	6%	3.0
non-SNP	Coding		279,694	138,544	50%	3.4
	Non-coding		1,207,908	219,791	18%	3.4
Total			4,571,056	1,303,984	29%	2.4




Figure 1. Population structure. (A) First two components of a genome-wide principal coordinate analysis. Each point represents one of 1,072 QC pass samples coloured according to country groupings (Table 1): Latin America (green, n=159); Africa (red, n=137); Western Asia (orange, n=47); West south-east Asia (blue, n=127); East south-east Asia (purple, n=277); Maritime south-east Asia (pink, n=76); Oceania (brown, n=208); Unassigned samples (grey, n=41). This shows the genetic separation of samples into seven distinct geographic clusters. This also shows that samples that have not been assigned to a region look distinct from those from the seven regions. After removal of the 41 unassigned samples we have an analysis set of 1,031 samples. (B) Genome-wide unrooted neighbour-joining tree showing population structure across all sites from the seven regions (1,031 analysis set samples), with sample branches coloured as in A. This shows that maritime Southeast Asia has large numbers of very highly related parasites and clear relatedness between samples is also present in some samples from Latin America and Africa.

variants from the PvGv 1.0 release. Given that the 1.0 release used the SaI1 reference, and the current release uses the P01 reference, we needed to convert the coordinates of the 1.0 release variants. We did this using the liftover tool, following the instructions at http://genomewiki.ucsc.edu/index.php/Minimal_Steps_For_LiftOver.

Various “bam improvement” steps were applied to the bwa outputs before further analyses. The Picard (<http://picard.sourceforge.net>) tools CleanSam, FixMateInformation and MarkDuplicates were successively applied to the bam files of each sample, using Picard version 2.6.0. GATK version 3.8-0 base quality score recalibration was applied using only the core genome and the PASS variants from the PvGv 1.0 release as a set of known sites. All lanes from each library were merged to create library-level bam files, and then all libraries for each sample were merged to create sample-level bam files. The output of this stage was a set of 1,895 “improved” bam files, one for each sample.

Standard alignment metrics were generated for each sample using the stats utility from samtools version 1.2²⁴. We also

used GATK’s CallableLoci to determine the genomic positions callable in each sample²⁵. The following GATK parameters were used: --minDepth 5.

Variant discovery and genotyping

We discovered potential SNPs and indels by running GATK’s HaplotypeCaller²⁵ version 3.8-0 independently across each of the 1,895 sample-level BAM files. The following GATK parameters were used: --emitRefConfidence GVCF --variant_index_type LINEAR --variant_index_parameter 128000 --max_alternate_alleles 6

This resulted in the creation of 1,895 GVCF files. We merged these for each of the 242 reference sequences (14 chromosomes, 1 apicoplast, 1 mitochondria and 226 short contigs) using GATK’s CombineGVCFs. Each of the 242 reference sequences was then genotyped using GATK’s GenotypeGVCFs with --max_alternate_alleles 6

The 226 separate VCF files for each short contig were concatenated into a single VCF using the concat command in bcftools v1.8.

Table 6. Geographic patterns of tandem duplications. Breakpoint IDs are shown in the first column (Duplication name) and can be used to match to the per sample breakpoints in the data release. Breakpoints are generally poly-A or poly-T repeats and First and Second breakpoints columns show the start positions and sequence of the breakpoint sequences in the reference genome (A_{18} denotes a poly-A sequence of 18 bases, i.e. AAAAAAAAAAAAAAAAAA). Length column shows the length in bp between the inner ends of the breakpoints. Percentages in Frequency (red) show the proportion of samples which could be genotyped that have a duplication (copy number ≥ 1.5). LAM=Latin America, AF=Africa, WAS=West Asia, WSEA=West south-east Asia, ESEA=East south-east Asia, OCE=Oceania, n =range of numbers of samples that could be genotyped at the different duplications.

Duplication name	Chrom	Length	First breakpoint	Second breakpoint	LAM $n=25-28$	AF $n=112-114$	WAS $n=11-14$	Frequency				
								WSEA $n<=91-105$	ESEA $n=198-220$	MSEA $n=59-63$	OCE $n=116-133$	
DBP_Cambodian	PvP01_06_v1	7,333	980,472 A_{18}	987,823 A_{15}	0%	73%	0%	29%	35%	7%	5%	
DBP_Malagasy	PvP01_06_v1	8,179	980,472 A_{18}	988,669 A_{22}	0%	10%	0%	0%	0%	0%	0%	
PvP01_09	PvP01_09_v1	44,831	392,555 GG	437,388 GG	0%	0%	0%	0%	<1%	0%	0%	
MDR1	PvP01_10_v1	38,134	468,190 A_{15}	506,339 A_{18}	0%	0%	0%	19%	0%	0%	0%	
PVP01_1468200_long	PvP01_14_v1	26,452	2,894,706 GAAG	2,921,162 GAAG	0%	0%	0%	0%	0%	0%	3%	
PVP01_1468200_medium	PvP01_14_v1	11,798	2,901,140 A_{11}	2,912,949 A_{30}	0%	0%	0%	0%	0%	0%	1%	
PVP01_1468200_short	PvP01_14_v1	3,517	2,903,559 T_{17}	2,907,093 T_{16}	0%	0%	0%	0%	0%	0%	26%	

Table 7. Frequency of different sets of polymorphisms putatively associated with drug resistance in samples from different geographical regions. All samples were classified into different types of drug resistance based on published genetic markers, and represent best attempt based on the available data. Each type of inferred resistance was considered to be either present, absent or unknown for a given sample. For each inferred resistance type, the table reports: the genetic markers considered; the drug they are associated with; the proportion of samples in each region classified as inferred resistant out of the samples where the type was not unknown. The number of samples classified as either resistant or not resistant varies for each type of inferred resistance considered (e.g. due to different levels of genomic accessibility); numbers in brackets in the header report the minimum and maximum number analysed while the exact numbers are reported in brackets below each percentage. SP: sulfadoxine-pyrimethamine; treatment: SP used for the clinical treatment of uncomplicated malaria. Details of the rules used to infer resistance status from genetic markers can be found on the resource page at www.malariagen.net/resource/30.

Marker	Associated with resistance to	Latin America (n=26–158)	Africa (n=114–137)	West Asia (n=14–46)	Western Southeast Asia (n=101–127)	Eastern Southeast Asia (n=220–276)	Maritime Southeast Asia (n=63–76)	Oceania (n=132–205)
dhfr 117T	Pyrimethamine	1% (1/158)	0% (0/137)	0% (0/46)	89% (110/124)	0% (0/276)	93% (69/74)	77% (138/180)
dhps 383G	Sulfadoxine	55% (84/152)	23% (31/134)	13% (6/46)	100% (127/127)	89% (230/259)	95% (72/76)	88% (181/205)
mdr1 2+ copies	Mefloquine	0% (0/26)	0% (0/114)	0% (0/14)	18% (18/101)	0% (0/220)	0% (0/63)	0% (0/132)
dhfr quadruple mutant	SP (treatment)	0% (0/158)	0% (0/137)	0% (0/45)	88% (103/117)	0% (0/276)	93% (64/69)	77% (131/171)

Variant filtering and annotation

SNPs and indels were filtered separately. For each class of variant, filtering was done in two stages: 1) Each variant was assigned a quality score using GATK's Variant Quality Score Recalibration (VQSR) version 3.8-0. The tools `VariantRecalibrator` and `ApplyRecalibration` are used here, and 2) Regions of the genome which we previously identified as being enriched for errors¹³ are masked out.

For SNPs, `VariantRecalibrator` was run using the PASS variants from the PvGv 1.0 release¹³ as a training set with 15.0 as a prior, and the following parameters: `-an QD -an FS -an SOR -an DP --maxGaussians 8 --MQCapForLogitJitterTransform 70`. For indels we have no suitable training set so we used a "bootstrap" approach. We first identified a set of high quality indels from all indels discovered, by setting the same thresholds on the variables FS, MQ and QD as were used for SNPs in PvGv 1.0 (FS<=14.63418, MQ>=51.6, QD>=12.43). We then used this as a training set with a prior of 12.0 and the following parameters: `-an QD -an DP -an SOR -an FS --maxGaussians 4 --MQCapForLogitJitterTransform 70`. `ApplyRecalibration` was then run to assign each variant a quality score named VQSLOD. High values of VQSLOD indicate higher quality. Variants (both SNPs and indels) with a VQSLOD score ≤ 0 were filtered out.

Variants in the VCFs were annotated using a number of different methods. Functional annotations were applied using `snpEff`²⁶ version 4.1, with gene annotations downloaded from

GeneDB²⁷ at <ftp://ftp.sanger.ac.uk/pub/project/pathogens/gff3/2018-05/PvivaxP01.noseq.gff3.gz>. The following options were used with `snpEff`: `-no-downstream -no-upstream -onlyProtein`.

Genome regions were annotated using `vcftools` and masked if they were outside the core genome. The different genome regions can be found in file `Pv4_regions.bed.gz` available at the resource page. Variants in the apicoplast, mitochondrion and short contigs were annotated `Apicoplast`, `Mitochondrion` and `ShortContig` respectively and masked by adding these annotations to the FILTER column. Subtelomeric regions in the 14 chromosomal sequences were identified by determining the genes at the boundaries of the subtelomeric regions identified in the PvGv 1.0 release¹³, and then using the coordinates of these same genes in the *P. vivax* P01 v1 reference sequence. Variants in these subtelomeric regions were annotated `SubtelomericHypervariable` and masked by adding this annotation to the FILTER column. Finally, the three internal chromosomal regions containing the *sera*, *msp3* and *msp7* families were annotated as `InternalHypervariable` and masked by adding this annotation to the FILTER column.

VCF files were converted to zarr format using `scikit-allele` v 1.2.0 (<https://github.com/cggh/scikit-allele>) and subsequent analyses performed using the zarr files.

Species identification

We identified species using nucleotide sequence from reads mapping to six different loci in the mitochondrial genome,

using custom java code (<https://github.com/malariagen/GeneticReportCard>). The loci were located within the *cox3* gene (PVP01_MIT02700), as described in a previously published species detection method²⁸. Alleles at various mitochondrial positions within the six loci were genotyped and used for classification¹⁸. A sample is assigned a species if it matches at least two of the six loci. At any given locus, the sample is considered a match to a species only if all the positions at that locus carry the matching allele.

Genetic distance

We calculate genetic distance between samples using biallelic coding SNPs that pass filters using a method previously described²⁹. For each SNP in sample i we calculate the non-reference allele frequency f_i as the proportion of reads that carry the non-reference allele. For clonal samples, f_i should be either 0 (for homozygous reference allele calls) or 1 (for homozygous alternative allele calls). For samples containing mixtures of different strains, we should expect fractional values of f_i for heterozygous calls. f_i is set to 0 if there are < 2 or $< 5\%$ alternative allele reads, and likewise to 1 if there are < 2 or $< 5\%$ reference allele reads. We do not calculate f_i when there were less than 5 reads in total. Genetic distance between sample 1 and 2 is calculated as $f_1(1 - f_2) + f_2(1 - f_1)$. For each sample pair we calculate the mean genetic distance across all SNPs for which we have an estimate of f_i in each sample.

Sample QC

We created a set of 1,072 QC pass samples after removing expected mislabelled, replicate, low coverage, mixed-species, and genetic outlier samples.

We first removed 107 samples where we had evidence that there might have been a mislabelling and hence are not sure of the true identity of the samples.

We calculated genome callability of each sample using GATK `CallableLoci` with a minimum depth of 5. Where we had multiple samples from the same individual, we removed samples with lower callability to leave a single sample for each individual in the QC pass set. This removed 145 samples. A further 548 samples with callability $< 50\%$ were also removed.

We removed a further 22 samples from the analysis set that were identified as containing mixed species. We note that many of these samples appeared as outliers on neighbour-joining trees before their removal (data not shown).

Finally, we noted that sample PNG_chesson had much higher median genetic distance to other samples than all other samples. The median genetic distance from PNG_chesson to other samples was 0.055, whereas the median genetic distances to other samples for all other samples was between 0.18 and 0.24. We removed PNG_chesson from the final analysis set as a genetic outlier. The final analysis set contained 1,072 QC pass samples.

Population structure and characterisation

The matrix of genetic distances was used to generate neighbour-joining trees and principal coordinates. Neighbour-joining trees (NJTs) were produced using the `nj` implementation in the R package `ape`. Principal coordinate analysis (PCoA) was performed using `scikit-bio` v0.5.5. Based on these observations we grouped the samples into seven geographic regions: Latin America, Africa, West Asia, the western part of Southeast Asia, the eastern part of Southeast Asia, maritime Southeast Asia and Oceania, with samples assigned to region based on the geographic location of the sampling site. 17 samples from returning travellers were assigned to region based on the reported country of travel. 41 QC pass samples from countries with small numbers of samples that did not cluster with those from one of these seven regions were left unassigned, so the population genetic analyses in this paper are based on 1,031 analysis set samples from the seven regions. F_{WS} was calculated using custom python scripts using the method previously described³⁰.

Tandem duplication genotyping

We genotyped tandem duplications using a novel two-stage process where we first discovered base pair resolution breakpoints using a combination of read depth and split reads and then genotyped samples at these discovered breakpoints using a combination of read depth and read pairs mapped in a tail-to-tail configuration. The outline algorithm for discovering breakpoints is as follows. For each QC pass sample sequenced from genomic DNA (not from material that underwent whole genome amplification or hybrid selection) that passes QC:

1. Calculate normalised coverage for every 300bp non-overlapping window as coverage of window/median coverage of all core genome windows
2. Determine putative increases in copy number by running an HMM across normalised coverage bins
3. Discard discovered regions shorter than 3kb
4. Automatically determine breakpoints for each putative tandem duplication using a custom python script that searches for clipped reads in read pairs where each read in the pair maps within 1kb of the breakpoints identified by the coverage HMM
5. For each pair of breakpoints, determine the maximal common sequence around the sequence, e.g. expand any homopolymer sequences to the ends of the homopolymer repeats
6. Discard any putative tandem duplication where breakpoints could not be determined

We then identify the unique set of breakpoint regions across all samples, and for breakpoint regions that overlap, determine the maximal region that is included in all. This set of breakpoint regions (Table 6) is then used in the genotyping stage. Here, for each sample, the outline algorithm is as follows

7. Calculate normalised coverage for every 300bp non-overlapping window as coverage of window/median coverage of all core genome windows
8. For each breakpoint region, set initial copy number to median of normalised coverage across 300bp windows in that region, rounded to the nearest integer
9. For each set of breakpoints, we determine the number of reads that are in 600bp window starting half a read length before the first breakpoint, and the proportion of these for which both a) the mate is within a 600bp window before the second breakpoint and b) the pair are in face-away orientation
10. If the number of reads in 9. is greater than 100 or the proportion is greater than zero but less than 2.5%, we assume the call is undetermined and set the copy number for the region to missing
11. If the number of reads in 9. is greater than 100, and the proportion of face-away is greater than 2.5%, but the initial copy number determined in 8, is 1, we assume there is a heterozygous duplication, and set the copy number to 1.5

We carried out the following analyses that show that the above algorithm is likely to be a reliable method for calling tandem duplications in *P. vivax* whole genome data. Firstly, we note that in all cases, where we found a copy number ≥ 2 using read depth, we also found read pairs consistent with at least one of the sets of breakpoints, i.e. we have exact breakpoints for all tandem duplication genotypes. Secondly, for cases where we found a copy of number one using read depth, but found evidence of breakpoint read pairs, the copy number was generally between one and two, and all but one sample had an F_{ws} value < 0.95 indicating mixed infections, and as such heterozygote calls (copy number 1.5) appear to be appropriate. Finally, a subset of samples have previously been assessed for *dhfr* using qRT-PCR, and our calls were highly concordant with those results (data not shown)^{15,20}.

SNP genotypes at drug resistance mutations and samples classification

We extracted genotypes at loci implicated in drug resistance from the VCF files (GT fields). At some loci we could not use amino acid changes annotated in the VCF files because a) the codon contains multiple variable positions, b) some positions within the codon have multi-allelic variants, or, c) as is the case for *dhfr* and *dhps*, there are combinations of multiple SNPs and indels. We developed a custom `python` script to call amino acids at selected loci by first determining the reference amino acids and then, for each sample, applying all variations using the GT field of the VCF file. Where a locus included multiple heterozygous variants, we used the PID and PGT VCF fields to phase the variants where possible. We calculated allele frequencies assuming a frequency of 1.0 for homozygous alternative calls, and 0.5 for heterozygous calls.

The amino acid and copy number calls generated were used to classify all samples into different types of drug resistance.

Our methods of classification were heuristic and based on the available data and current knowledge of the molecular mechanisms. Each type of resistance was considered to be either present, absent or unknown for a given sample. The procedure used to map genetic markers to inferred resistance status classification is described in detail for each drug in the accompanying data release (<https://www.malariagen.net/resource/30>).

Data availability

Underlying data

This project contains the following underlying data that are available as an online resource: <https://www.malariagen.net/resource/30>. Data are also available from Figshare.

Figshare: Supplementary data to: An open dataset of *Plasmodium vivax* genome variation in 1,895 worldwide samples. <https://doi.org/10.6084/m9.figshare.19367876>.

- Study information: Details of the 11 contributing partner studies, and 3 external studies, including description, contact information and key people.
- Sample provenance and sequencing metadata: sample information including partner study information, location and year of collection, ENA accession numbers, and QC information for 1,895 samples from 27 countries.
- Measure of complexity of infections: characterisation of within-host diversity (F_{ws}) for 1,072 QC pass samples.
- Drug resistance marker genotypes: genotypes at known markers of drug resistance for 1,895 samples, containing amino acid and copy number genotypes at 3 loci: *dhfr*, *dhps*, *mdr1*.
- Inferred resistance status classification: classification of 1,072 QC pass samples into different types of resistance to 4 drugs or combinations of drugs: pyrimethamine, sulfadoxine, mefloquine, and sulfadoxine-pyrimethamine combination.
- Drug resistance markers to inferred resistance status: details of the heuristics utilised to map genetic markers to resistance status classification.
- Tandem duplication genotypes: genotypes for tandem duplications discovered in four regions of the genome.
- Genome regions and Genome regions index: a bed file classifying genomic regions as core genome or different classes of non-core genome in addition to tabix index file for genome regions file.
- Short variants genotypes: Genotype calls on 4,571,056 SNPs and short indels in 1,895 samples from 27 countries, available both as VCF and zarr files.

Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0).

Consent

All samples in this study were derived from blood samples obtained from patients with *P. vivax* malaria, collected with informed consent from the patient or a parent or guardian. At each location, sample collection was approved by the appropriate local and institutional ethics committees. The following local and institutional committees gave ethical approval for the partner studies: Human Research Ethics Committee, Walter and Eliza Hall Institute, Australia; Human Research Ethics Committee of NT Department of Health and Families and Menzies School of Health Research, Darwin, Australia; Islamic Republic of Afghanistan Ministry of Public Health Institutional Review Board, Afghanistan; ICDDR,B Ethical Review Committee, Bhutan; Research Ethics Board of Health, at the Ministry of Health in Bhutan; Institutional Review Board of the Institute of Biomedical Sciences, University of São Paulo, Brazil; National Ethics Committee for Health Research, Phnom Penh, Cambodia; Institutional Review Board of Jiangsu Institute of Parasitic Diseases, Wuxi, China; Comité Institucional de Ética de Investigaciones en Humanos, Colombia; Comité de Bioética Instituto de Investigaciones Médicas Facultad de Medicina Universidad de Antioquia, Colombia; Armauer Hansen Research Institute Institutional Review Board, Ethiopia; Addis Ababa University College of Natural Sciences, Ethiopia; Addis Ababa University, Aklilu Lemma Institute of Pathobiology Institutional Review Board, Ethiopia; National Research Ethics Review Committee of Ethiopia; Eijkman Institute Research Ethics Committee, Jakarta, Indonesia; Comité National d’Éthique auprès du Ministère de la Santé Publique, Madagascar; National Ethics Committee for Health Research, Lao Peoples’ Democratic Republic; Research Review Committee of the Institute for Medical Research and the Medical Research Ethics Committee (MREC), Ministry of Health, Malaysia; The Government of the Republic of the Union of Myanmar, Ministry of Health, Department of Medical Research, Lower Myanmar, Myanmar; Papua New Guinea Institute of Medical Research Institutional Review Board, the Medical Research Advisory Committee of Papua New Guinea; Ethics Review Committee, Faculty of Medicine, University of Colombo, Sri Lanka; Ethics Committee, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Oxford Tropical Research Ethics Committee, Oxford, UK; Institutional Review Board, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA; Scientific and Ethical Committee of the Hospital for Tropical Diseases in Ho Chi Minh City, Vietnam; The Ministry of Health Evaluation Committee on Ethics in Biomedical Research, Vietnam;

Author contributions

Data analysis group

Pearson, RD, Amato, R, Siegel, SV, Kwiatkowski, DP

Local study design, implementation and sample collection

Adam, I, Alam, MS, Alemu, S, Amaratunga, C, Andrianaranjaka, V, Anstey, NM, Aseffa, A, Ashley, E, Assefa, A, Auburn, S, Barber, BE, Barry, A, Batista Pereira, D, Cao, J, Chau, NH, Chotivanich, K, Chu, C, Dondorp, A, Echeverry, DF, Erko, B, Espino, F, Fairhurst, R, Faiz, A, Fernanda Villegas, M, Gao, Q, Golassa, L, Grigg, MJ, Hamed, Y, Hien, TT, Htut, Y, Karunaweera, N, Khan, W, Krudsood, S, Lacerda, M, Ley, B, Lim, P, Liu, Y, Llanos-Cuentas, A, Lon, C, Lopera-Mesa, T, Marfurt, J, Michon, P, Mohammed, R, Mueller, I, Namaik-larp, C, Newton, PN, Nguyen, T, Nosten, F, Noviyanti, R, Pava, Z, Petros, B, Phyto, AP, Price, RN, Pukrittayakamee, S, Rahim, AG, Randrianarivelojosia, M, Rayner, JC, Rumaseb, A, Thriemer, K, Tobon-Castano, A, Trimarsanto, H, Urbano Ferreira, M, Vélez, ID, Wangchuk, S, Wellems, TE, White, NJ, William, T, Yasnot, MF, Yilma, D

Sequencing, data production and informatics

Pearson, RD, Drury, E, Amato, R, Goncalves, S

Partner study support and coordination

Simpson, VJ, Amato, R, Goncalves, S, Johnson, KJ, Miotto, O, Pearson, RD, Kwiatkowski, DP

Acknowledgements

This study was conducted by the MalariaGEN *Plasmodium vivax* Genome Variation Project, and was made possible by clinical parasite samples contributed by partner studies, whose investigators are represented in the author list and in the associated data release (<https://www.malariagen.net/resource/30>). In addition, the authors would like to thank GSK Global Health Medicines Research and Development Unit and the Kozenis Team for the contribution of samples through partner study 1128 collaboration. Genome sequencing was done by the Wellcome Sanger Institute and we thank the staff of Wellcome Sanger Institute Sample Logistics, Sequencing, and Informatics facilities for their contribution. The authors would like to thank Julia Jeans for her assistance with the journal submission support. We thank all patients, collaborators and investigators who submitted samples used in this study.

References

1. Battle KE, Lucas TCD, Nguyen M, *et al.*: **Mapping the global endemicity and clinical burden of *Plasmodium vivax*, 2000-17: a spatial and temporal modelling study.** *Lancet.* 2019; **394**(10195): 332-343. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
2. World Health Organization: **World malaria report 2021.** 2021. [Reference Source](#)
3. Auburn S, Cheng Q, Marfurt J, *et al.*: **The changing epidemiology of *Plasmodium vivax*: Insights from conventional and novel surveillance tools.**

- PLoS Med.* 2021; **18**(4): e1003560.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
4. Chu CS, White NJ: **The prevention and treatment of *Plasmodium vivax* malaria.** *PLoS Med.* 2021; **18**(4): e1003561.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 5. White NJ, Imwong M: **Relapse.** *Adv Parasitol.* 2012; **80**: 113–150.
[PubMed Abstract](#) | [Publisher Full Text](#)
 6. Kho S, Qotrunnada L, Leonardo L, et al.: **Hidden Biomass of Intact Malaria Parasites in the Human Spleen.** *N Engl J Med.* 2021; **384**(21): 2067–2069.
[PubMed Abstract](#) | [Publisher Full Text](#)
 7. Kho S, Qotrunnada L, Leonardo L, et al.: **Evaluation of splenic accumulation and colocalization of immature reticulocytes and *Plasmodium vivax* in asymptomatic malaria: A prospective human splenectomy study.** *PLoS Med.* 2021; **18**(5): e1003632.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 8. Popovici J, Roesch C, Rougeron V: **The enigmatic mechanisms by which *Plasmodium vivax* infects Duffy-negative individuals.** *PLoS Pathog.* 2020; **16**(2): e1008258.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 9. Dia A, Jett C, Trevino SG, et al.: **Single-genome sequencing reveals within-host evolution of human malaria parasites.** *Cell Host Microbe.* 2021; **29**(10): 1496–1506.e3.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 10. Malaria Genomic Epidemiology Network: **A global network for investigating the genomic epidemiology of malaria.** *Nature.* 2008; **456**(7223): 732–737.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 11. Lacerda MVG, Llanos-Cuentas A, Krudsood S, et al.: **Single-Dose Tafenoquine to Prevent Relapse of *Plasmodium vivax* Malaria.** *N Engl J Med.* 2019; **380**(3): 215–228.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 12. Llanos-Cuentas A, Lacerda MVG, Hien TT, et al.: **Tafenoquine versus Primaquine to Prevent Relapse of *Plasmodium vivax* Malaria.** *N Engl J Med.* 2019; **380**(3): 229–241.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 13. Pearson RD, Amato R, Auburn S, et al.: **Genomic analysis of local variation and recent evolution in *Plasmodium vivax*.** *Nat Genet.* 2016; **48**(8): 959–964.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 14. Hupalo DN, Luo Z, Melnikov A, et al.: **Population genomics studies identify signatures of global dispersal and drug resistance in *Plasmodium vivax*.** *Nat Genet.* 2016; **48**(8): 953–958.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 15. Lo E, Hostetler JB, Yewhalaw D, et al.: **Frequent expansion of *Plasmodium vivax* Duffy Binding Protein in Ethiopia and its epidemiological significance.** *PLoS Negl Trop Dis.* 2019; **13**(9): e0007222.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 16. Parobek CM, Lin JT, Saunders DL, et al.: **Selective sweep suggests transcriptional regulation may underlie *Plasmodium vivax* resilience to malaria control measures in Cambodia.** *Proc Natl Acad Sci U S A.* 2016; **113**(50): E8096–E8105.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 17. Auburn S, Benavente ED, Miotto O, et al.: **Genomic analysis of a pre-elimination Malaysian *Plasmodium vivax* population reveals selective pressures and changing transmission dynamics.** *Nat Commun.* 2018; **9**(1): 2585.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 18. Pearson RD, Amato R, Kwiatkowski DP, et al.: **An open dataset of *Plasmodium falciparum* genome variation in 7,000 worldwide samples.** 2019.
[Publisher Full Text](#)
 19. Menard D, Chan ER, Benedet C, et al.: **Whole genome sequencing of field isolates reveals a common duplication of the Duffy binding protein gene in Malagasy *Plasmodium vivax* strains.** *PLoS Negl Trop Dis.* 2013; **7**(11): e2489.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 20. Hostetler JB, Lo E, Kanjee U, et al.: **Independent Origin and Global Distribution of Distinct *Plasmodium vivax* Duffy Binding Protein Gene Duplications.** *PLoS Negl Trop Dis.* 2016; **10**(10): e0005091.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 21. Price RN, Auburn S, Marfurt J, et al.: **Phenotypic and genotypic characterisation of drug-resistant *Plasmodium vivax*.** *Trends Parasitol.* 2012; **28**(11): 522–529.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 22. Auburn S, Böhme U, Steinbiss S, et al.: **A new *Plasmodium vivax* reference sequence with improved assembly of the subtelomeres reveals an abundance of *pir* genes [version 1; peer review: 2 approved].** *Wellcome Open Res.* 2016; **1**: 4.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 23. Li H, Durbin R: **Fast and accurate short read alignment with Burrows-Wheeler transform.** *Bioinformatics.* 2009; **25**(14): 1754–1760.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 24. Li H, Handsaker B, Wysoker A, et al.: **The Sequence Alignment/Map format and SAMtools.** *Bioinformatics.* 2009; **25**(16): 2078–2079.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 25. DePristo MA, Banks E, Poplin R, et al.: **A framework for variation discovery and genotyping using next-generation DNA sequencing data.** *Nat Genet.* 2011; **43**(5): 491–498.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 26. Cingolani P, Platts A, Wang LL, et al.: **A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of *Drosophila melanogaster* strain w1118; iso-2; iso-3.** *Fly (Austin).* 2012; **6**(2): 80–92.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 27. Logan-Klumpler FJ, De Silva N, Boehme U, et al.: **GeneDB—an annotation database for pathogens.** *Nucleic Acids Res.* 2012; **40**(Database issue): D98–108.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 28. Echeverry DF, Deason NA, Davidson J, et al.: **Human malaria diagnosis using a single-step direct-PCR based on the *Plasmodium cytochrome oxidase III* gene.** *Malar J.* 2016; **15**: 128.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 29. MalariaGEN *Plasmodium falciparum* Community Project: **Genomic epidemiology of artemisinin resistant malaria.** *eLife.* 2016; **5**: e08714.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 30. Manske M, Miotto O, Campino S, et al.: **Analysis of *Plasmodium falciparum* diversity in natural infections by deep sequencing.** *Nature.* 2012; **487**(7407): 375–379.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Open Peer Review

Current Peer Review Status:  

Version 1

Reviewer Report 23 May 2022

<https://doi.org/10.21956/wellcomeopenres.19696.r50006>

© 2022 Juliano J. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



Jonathan J. Juliano

Division of Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, NC, USA

The manuscript "An open dataset of *Plasmodium vivax* genome variation in 1,895 worldwide samples" represents a brief analysis of the genetic variation of currently available *P. vivax* genomic data. The samples are drawn largely from new MalariaGen and VivaxGen projects but include 3 other large population studies previously published. The investigators carefully re-analyzed all of the data to provide uniformity and generate a basic resource of parasite genetic diversity for the malaria community. These data and analyses are reportedly available in the public space on the MalariaGen resources pages. Overall, the analysis pipelines are appropriate and should yield accurate information concerning the underlying genome variation. The manuscript reports basic analysis (variant calls, basic population structure, basic allele frequencies of putative drug resistance polymorphisms). As they note, this leaves a lot of potentially interesting analyses to be done yet. Overall, this is a well done project and is well written. The summary of the data and methods of data generation are generally very clear. This is clearly a useful resource for the malaria community moving forward. I have a few minor comments that should be addressed by the authors:

1. I know this might seem nit picky, but the fact is that they really are presenting data on 1,072 samples, so the title is misleading. I would consider changing the title and abstract to reflect the analyzed samples.
2. The tandem duplication genotyping method is intriguing. Based on the process I would assume the result is very conservative in calling duplications. It would be nice to allow for this to be compared to other methods used. The code for this analysis does not seem to be publicly available (or at least is not cited as to where it is in the manuscript) which it really should be to allow other investigators to evaluate it relative to their work.

Is the rationale for creating the dataset(s) clearly described?

Yes

Are the protocols appropriate and is the work technically sound?

Yes

Are sufficient details of methods and materials provided to allow replication by others?

Yes

Are the datasets clearly presented in a useable and accessible format?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Malaria genomics, epidemiology, molecular biology

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 17 May 2022

<https://doi.org/10.21956/wellcomeopenres.19696.r50005>

© 2022 Neafsey D. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



Daniel Neafsey

¹ Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, USA

² Infectious Disease and Microbiome Program, Broad Institute of MIT and Harvard, Cambridge, Cambridge, MA, USA

This Data Note describes a large aggregation of existing and newly generated whole genome sequence data for the *Plasmodium vivax* malaria parasite, spanning many countries around the world. This resource will clearly have significant utility to the *P. vivax* research community for the foreseeable future. The report is clearly written and the methods are well described. I have several small suggestions to clarify or improve the manuscript, recognizing that follow-up manuscripts are likely to explore various biological themes in greater detail.

1. Table 1 depicts extreme variation in the % of samples that pass QC for analysis from different countries. Can the factors associated with high vs. low QC rates be described from this large aggregation of data, in order to help other investigators collect/store/extract DNA amenable to whole genome sequencing? It is notable that of the 1,895 samples mentioned in the title, only approximately half (1072) yielded data of sufficient quality for analysis.
2. The regions depicted in various colors in the NJ tree and PCA of Figure 1 made me wish for a small map with countries color-coded to accompany those plots. While Table 2 lists countries associated with each geographic region, it is tricky to remember which countries are encompassed by 'Western Asia' vs. 'Western Southeast Asia' without consulting Table 2

repeatedly.

3. The Figure 1 legend and article text use the term 'related' or 'relatedness' to describe parasite populations exhibiting shallow branch lengths in the NJ tree. However, given the tree was built using a metric of identity by state (IBS) at variant positions, rather than an actual estimate of relatedness (eg IBD), then it would be more appropriate to refer to such parasite populations as 'highly similar' instead of 'highly related.' I agree that the highly similar parasite populations are likely also highly related, but it is useful to use these terms precisely to avoid confusion in other contexts where the distinction among them is more vital.
4. On page 16 PNG_chesson is described as having a much higher genetic distance to other parasite samples, yet the value cited (0.055) is lower (rather than higher) than the typical genetic distance between all other parasite samples (0.18-0.24). This is confusing and requires clarification.

Is the rationale for creating the dataset(s) clearly described?

Yes

Are the protocols appropriate and is the work technically sound?

Yes

Are sufficient details of methods and materials provided to allow replication by others?

Yes

Are the datasets clearly presented in a useable and accessible format?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Malaria genomics, evolution

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
